VBLT Stock Overview
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vascular Biogenics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$0.32 |
| 52 Week Low | US$0.10 |
| Beta | 0.71 |
| 1 Month Change | -33.33% |
| 3 Month Change | -45.07% |
| 1 Year Change | 9.17% |
| 3 Year Change | -86.55% |
| 5 Year Change | -88.53% |
| Change since IPO | -97.33% |
Recent News & Updates
Recent updates
VBL Therapeutics receives non-compliance letter from Nasdaq
Sep 01VBL Therapeutics GAAP EPS of -$0.12
Aug 15VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals
Jul 19Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
May 18
Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump
Sep 03How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?
Mar 17How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?
Jan 28VBL Therapeutics expands the ovarian cancer trial in Europe
Dec 29Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?
Dec 24
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 19VBL Therapeutics EPS beats by $0.01, misses on revenue
Nov 16Shareholder Returns
| VBLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -34.5% | 1.9% | 0.7% |
| 1Y | 9.2% | -6.6% | 23.9% |
Return vs Industry: VBLT exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: VBLT underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| VBLT volatility | |
|---|---|
| VBLT Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VBLT's share price has been volatile over the past 3 months.
Volatility Over Time: VBLT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 7 | Dror Harats | www.vblrx.com |
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd.
Vascular Biogenics Ltd. Fundamentals Summary
| VBLT fundamental statistics | |
|---|---|
| Market cap | US$12.11m |
| Earnings (TTM) | -US$15.95m |
| Revenue (TTM) | US$481.00k |
25.2x
P/S Ratio-0.8x
P/E RatioIs VBLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VBLT income statement (TTM) | |
|---|---|
| Revenue | US$481.00k |
| Cost of Revenue | US$17.00k |
| Gross Profit | US$464.00k |
| Other Expenses | US$16.42m |
| Earnings | -US$15.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 96.47% |
| Net Profit Margin | -3,317.05% |
| Debt/Equity Ratio | 0% |
How did VBLT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/17 14:50 |
| End of Day Share Price | 2023/10/16 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vascular Biogenics Ltd. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Alethia Young | Deutsche Bank |
| Etzer Darout | Guggenheim Securities, LLC |